Drugs / DEZECAPAVIR
DEZECAPAVIR
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06724640 | Dec 2024 → Aug 2028 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 1 | NCT06368986 | Apr → Oct 2024 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT06012136 | Aug 2023 → Jun 2026 overdue | HIV infectious disease | ViiV Healthcare | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05393271 | Oct 2022 → Apr 2023 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06039579 | Oct 2023 → Jun 2024 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-02-25 | GlaxoSmithKline | Results ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing gsk.com ↗
Additional data from ViiV Healthcare’s long-acting pipeline presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado, show VH499, an investigational capsid inhibitor, was generally well tolerated and support the potential for ultra long-acting (ULA) twice-yearly dosing. |
| 2026-02-25 | ViiV Healthcare | Results ViiV HEALTHCARE PRESENTS PIPELINE DATA FOR TWO INVESTIGATIONAL HIV TREATMENT THERAPIES WITH POTENTIAL FOR TWICE-YEARLY DOSING viivhealthcare.com ↗
Additional data from ViiV Healthcare’s long-acting pipeline presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado, show VH499, an investigational capsid inhibitor, was generally well tolerated and support the potential for ultra long-acting (ULA) twice-yearly dosing. |
| 2025-03-11 | GlaxoSmithKline | Results ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1 gsk.com ↗
VH4011499 (VH499), a promising, highly potent investigational capsid inhibitor, shows positive antiviral activity and good safety findings for treatment of HIV-1, supporting further development as a long-acting antiretroviral |
| 2025-03-11 | ViiV Healthcare | Results ViiV HEALTHCARE SHOWCASES LEADERSHIP IN LONG-ACTING INJECTABLES INNOVATION AT CROI 2025 WITH DATA ON THIRD-GENERATION INTEGRASE INHIBITOR (INSTI) AND HIGHLY POTENT CAPSID INHIBITOR AGAINST HIV-1 viivhealthcare.com ↗
VH4011499 (VH499), a promising, highly potent investigational capsid inhibitor, shows positive antiviral activity and good safety findings for treatment of HIV-1, supporting further development as a long-acting antiretroviral |
| 2025-03-09 | GlaxoSmithKline | Results ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025 gsk.com ↗
A proof-of-concept clinical trial provides insights into the antiviral effects, pharmacokinetics, safety, and tolerability of VH4011499 (VH499), a new, highly potent investigational capsid inhibitor and one of several partner asset options being evaluated for development into long-acting treatment HIV |
| 2025-03-09 | ViiV Healthcare | Results ViiV HEALTHCARE CONTINUES TO DELIVER LONG-ACTING INJECTABLE HIV INNOVATION WITH LATE-BREAKING DATA AND REAL-WORLD INSIGHTS ACROSS PIPELINE AND PORTFOLIO AT CROI 2025 viivhealthcare.com ↗
A proof-of-concept clinical trial provides insights into the antiviral effects, pharmacokinetics, safety, and tolerability of VH4011499 (VH499), a new, highly potent investigational capsid inhibitor and one of several partner asset options being evaluated for development into long-acting treatment HIV regimens. |
All press releases naming this drug 6 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DEZECAPAVIR | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068048 ↗ |
| Known as | VH-4011499A | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068048 ↗ |
| Known as | VH-499 | “INTRODUCTION: This first-time-in-human study describes the pharmacokinetics, drug-drug interaction potential, and safety of VH4011499 (VH-499), a new HIV-1 capsid inhibitor.” PMID 40172795 ↗ Apr 2025 |
| Known as | VH4011499 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06012136 ↗ |
| Action | Inhibit | “a new HIV-1 capsid inhibitor” PMID 40172795 ↗ Apr 2025 |
| Modality | Small molecule | — CHEMBL6068048 ↗ |
| Route | Oral | “administered orally” PMID 40172795 ↗ Apr 2025 |